In January 2021, the FDA approved the following new indications/Molecules. Combination of nivolumab and cabozantinib as first-line treatment for patients...
Renal cell carcinoma
In January 2021, the FDA approved the following new indications/Molecules. Combination of nivolumab and cabozantinib as first-line treatment for patients...
